Black Book Recaps 2025 Research Announcements and Client‑Rated Honors; Reaffirms Vendor‑Agnostic, Independently Validated Intelligence and 2026 Commitments 
Revolo Accelerates Development of Orally Administered ‘1104 for Allergic Diseases
‘1104 sublingual formulation achieved extensive systemic exposure and demonstrated impact across measures of disease in additional preclinical studies in atopic...
Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma,...
Amwell set to continue to enable U.S. Defense Health Agency healthcare teams to deliver connected and seamless in-person and virtual care for the Military Health System (“MHS”)
U.S. Defense Health Agency awards Amwell, as part of a Leidos-led Partnership, an extension for the Military Health System’s Digital...
Sofwave Medical Reports Record Second Quarter and First Half 2025 Financial Results and Business Highlights
• Quarterly record revenue in Q2 of $21M, +43% year-over-year growth; IFRS gross margin of 75.5% • Second quarter pulse recurring...
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in...
Clene to Present at the Canaccord 45th Annual Growth Conference
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
Continued progress positions Company to report topline data for Phase 1 clinical trial of SENTI-202 before year-endSOUTH SAN FRANCISCO, Calif.,...
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., Aug....
Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities
Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY® System as it Nears FDA Marketing Clearance DecisionHINGHAM, Mass.,...
Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025
LAKE FOREST, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced...
Conduit to Change Name to CDT Equity Inc.
Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets...
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
Acquisition to Include DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product PortfolioTransaction Expands SERB’s Investment in the U.S.SERB to Commence...
Bioma Probiotics Launches Science-Backed Gut Health Formula for Women’s Natural Weight Loss
Discover how Bioma Probiotics supports weight loss, balances gut health, and helps women reduce bloating, boost energy, and improve digestion...
Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug....
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance...
CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Privately held CHO Plus, Inc. announced today a project agreement...
HOOPP launches 2030 Strategic Plan to build a stronger financial future for Ontario’s healthcare community
Five-year plan seeks to drive member value and portfolio resilienceTORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The Healthcare of Ontario...
Republic Technologies Partners with BitGo to Safeguard Ethereum Operations
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (the "Company" or "Republic")...